# Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis

> **NCT00075621** · PHASE2 · COMPLETED · sponsor: **Boston Medical Center** · enrollment: 62 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** filgrastim
- **DRUG:** melphalan
- **PROCEDURE:** autologous peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00075621
- **Lead sponsor:** Boston Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** 2005-06
- **Final completion:** 2020-09-04
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2020-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00075621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00075621, "Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00075621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*